Every material Form 8-K Perrigo filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Perrigo reported third-quarter 2025 net sales of $1.04 billion, down 4.1% year over year, and adjusted diluted EPS of $0.80 versus $0.81 a year earlier. The company lowered its full-year 2025 outlook, now projecting adjusted diluted EPS of $2.70 to $2.80 and reported net sales growth of -2.5% to -3.0%, citing infant formula industry dynamics and soft OTC consumption. It also said it is starting a strategic review of its infant formula business, adding to the existing review of Oral Care.
Q3 2025 net sales were $1.04 billion, down 4.1%; reported diluted EPS was $0.09 versus a loss of $(0.13) a year earlier
Q3 2025 adjusted diluted EPS was $0.80, down from $0.81; adjusted operating income was $173 million, down 4.9%
Full-year 2025 outlook revised: adjusted diluted EPS of $2.70 to $2.80 and reported net sales growth of -2.5% to -3.0%
Strategic review of the infant formula business announced November 5, 2025; Oral Care review continues and Dermacosmetics sale is expected to close in Q1 2026
Perrigo reported second-quarter 2025 results for the period ended June 28, 2025, with net sales of $1.06 billion, down 0.9% year over year, and adjusted diluted EPS of $0.57, up 7.5%. The company reaffirmed its full-year 2025 adjusted EPS target of $2.90 to $3.10 but now expects reported and organic net sales growth toward the lower end of its ranges, citing infant formula recovery that is slower than anticipated and weak market consumption.
Net sales were $1.06 billion, down 0.9%, with divestitures and exited products reducing sales by 2.5% and currency adding 1.7%.
Reported diluted EPS was $0.00 versus a loss of $(0.77) a year earlier; adjusted diluted EPS was $0.57 versus $0.53.
Full-year 2025 outlook: reported net sales growth of 0% to 3%, adjusted diluted EPS of $2.90 to $3.10, with net sales expected toward the lower end of the ranges.
The Dermacosmetics business sale is expected to close in the first quarter of 2026.
Perrigo agreed on July 13, 2025 to sell its Dermacosmetics branded business in Northern Europe, the Netherlands and Poland to Kairos Bidco AB, a vehicle managed by an affiliate of KKR, for €300 million in upfront cash plus up to €27 million in contingent payments. The business generated about €125 million in 2024 net sales and about 5% of Perrigo's 2024 adjusted operating income, and the company says expected net proceeds will go toward balance sheet strengthening and other capital allocation priorities. The deal is expected to close in the first quarter of 2026, subject to regulatory approvals and works council consultation.
Upfront cash of €300 million at closing, subject to customary adjustments for inventory, working capital, debt and cash
Up to €27 million in additional contingent payments tied to performance thresholds over three years
Business generated about €125 million in 2024 net sales and about 5% of 2024 adjusted operating income
Expected closing in the first quarter of 2026; either party may terminate if closing is not completed within 18 months of signing
Perrigo eliminated the EVP and President roles for its Consumer Self-Care Americas and International businesses as part of an organizational update. Triona Schmelter stepped down June 30, 2025, and will serve in an advisory role until October 31, 2025, while Roberto Khoury was named EVP and Chief Commercial Officer effective July 1, 2025. The company said the change does not affect its full-year 2025 adjusted EPS guidance or reporting segments.
Triona Schmelter stepped down as EVP and President, Consumer Self-Care Americas, on June 30, 2025, and is in an advisory role until October 31, 2025.
Schmelter's severance, subject to a supplemental release, includes one year of base salary, a prorated 2025 incentive bonus, one year of Company-paid COBRA benefits and two years of continued equity vesting.
Roberto Khoury, previously EVP and President, Consumer Self-Care International, was appointed EVP and Chief Commercial Officer effective July 1, 2025, reporting to CEO Patrick Lockwood-Taylor.
Perrigo said the alignment does not impact its full-year 2025 adjusted EPS guidance.
Perrigo said its EVP of Global Operations and Supply Chain, Ron Janish, will step down effective June 23, 2025, and serve in an advisory role until September 30, 2025. Matt Winterman, previously SVP of Global Supply Chain and Strategy at AstraZeneca, will succeed him effective June 23, 2025. The filing discloses no financial results or guidance, and the executive change is a leadership transition for the operations function.
Ron Janish steps down as EVP, Global Operations and Supply Chain effective June 23, 2025, and advises the company until September 30, 2025.
Janish's separation severance is a lump sum of 2.5 times his base salary and target annual bonus, plus statutory redundancy payments and continued vesting of equity awards, subject to a general release of claims.
Matt Winterman takes the role effective June 23, 2025; he previously oversaw a $54 billion supply chain across 5,000 SKUs at AstraZeneca.
The press release gives Winterman's title as EVP, Product Supply, Operations Strategy and Transformation Officer, while the 8-K describes it as EVP of Global Operations and Supply Chain.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Perrigo filing is on SEC EDGAR ↗. 8-K briefs of other companies →